Ticks Are Really Bad This Summer. What to Do About Them
And this year appears to be especially bad: Emergency-department visits for tick bites are the highest since 2019, according to the Centers for Disease Control and Prevention tick-bite data tracker.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
CBS News
25 minutes ago
- CBS News
Colorado Medicaid recipient fears losing coverage after "big, beautiful bill" passes
Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been President Trump signed what he called the "One Big Beautiful Bill Act" during a celebratory event on July 4 after the bill narrowly passed the House on Thursday, with Colorado's congressional delegation voting along party lines. The legislation makes a number of changes to domestic policies, including permanently increasing the child tax credit to $2,200, allowing tipped workers to deduct tips and overtime from federal taxes, and boosting funding for U.S. Immigration and Customs Enforcement. It also eliminates tax incentives for clean energy, electric vehicles, and energy efficiency programs. In addition, the bill includes stronger restrictions on Medicaid, which provides health care coverage to over 70 million low-income and disabled Americans, according to data from the U.S. Department of Health and Human Services. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection left her unable to work, said she's worried about the changes. "It scares me, not only for myself, but for all of the people who are on Medicaid, who are just trying to survive," she said. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection, talks to CBS News Colorado via Zoom about concerns she has about possible cuts to Medicaid after President Trump signed the "One Big Beautiful Bill Act" on July, 4, 2025. CBS Schoen said the coverage helped her regain her health and return to work. "Because of Medicaid, I've been able to get well enough to actually work again," Schoen said. "I work for the State of Colorado, for the Division of Youth Services, and I love my job so much." One in four Coloradans receives Medicaid benefits -- about 1.72 million people, according to the Colorado Department of Health Care Policy and Financing. Annie Lee, president and CEO of Colorado Access, which helps administer Medicaid in the state, said the new bill could have a sweeping effect. "What this bill does is really shift the financial burden to states," Lee said. "The majority of the things in the bill that was just passed are set to take effect next year or the following year. There's kind of a graduated impact for most of the things in the bill." Stretchers for an operating room are seen at Denver Health in Denver, Colorado on Thursday, April 25, 2024. Hyoung Chang/The Denver Post via Getty Images The legislation adds work requirements for certain adults to keep receiving Medicaid benefits. Supporters argue it will motivate able-bodied adults to improve their lives. But Schoen said many Medicaid recipients already work. "A lot of us do work. We try really hard. We don't just lie around on the couch all day," she said. "I was hospitalized seven times last year, and I had two surgeries, and I worked the entire time. But there are many times where it just feels like I'm walking on thin ice. If one more thing happens, the whole house of cards could just collapse." Lee warned the bill is anticipated to result in "large-scale loss of health insurance coverage for Coloradans." Schoen echoed that concern. "I just feel like the people who we've elected to be our proxies have just turned around and pushed us off a cliff," she said. "And there's no safety net down there."
Yahoo
29 minutes ago
- Yahoo
If You Skip Deodorant for a Week, Here's What Happens to Your Body
If You Skip Deodorant for a Week, Here's What Happens to Your Body originally appeared on Parade. Morning affirmations and mantras are often billed as a way to boost confidence first thing. We're not here to argue. However, just wondering: Have you heard of the benefits of applying deodorant?"It gives you confidence in knowing that you are covered," raves , a dermatologist. "Each day your skin is full of more sweat, oils, environmental factors like pollutants, dirt and grime, as you go about your day and routine, so applying deodorant can help with unwanted odor."Applying deodorant may not have the same panache as a 12-step skincare routine that involves ice rolling your face. Applying deodorant might be as second-nature as brushing your teeth, to the point where you can't even remember if you've did it and often question yourself. What if the answer was no, for seven straight days? A pair of dermatologists and one dermatopathologist shared the truth on precisely what happens to the body if you skip deodorant for a week. Dermatologists suggest that you may overlook issues like body odor and stained clothes on the first day of not using deodorant. However, by day seven, you—and those around you—may be running to grab deodorant for you to apply. Here are the risks of skipping deodorant for one week. You can't see this one, but it's there. "Deodorants often contain antimicrobial ingredients," explains Dr. Gretchen W. Frieling, MD, a triple board-certified dermatopathologist at GFaceMD. "Skipping it gives bacteria more room to grow in moist areas like armpits, leading to more odor and potential skin imbalances."Which leads us to the big one... Come on, you could smell this risk of going deodorant-free for a week coming from a mile away, right?"The most obvious effect is that you might start to smell stronger," shares Dr. Viktoryia Kazlouskaya, MD, Ph.D., a dermatologist. "It may not happen immediately if you have been using deodorants daily, but it will happen."You might be surprised to learn what's behind this unpleasant smell. "Sweat on its own is odorless—what causes the smell is the bacteria living on your skin," Dr. Kazlouskaya says. "Everyone's skin microbiome is different, and even if you shower daily, some people naturally develop a more noticeable scent." This one is the pits. "Antiperspirants—a type of deodorant—contain aluminum salts that temporarily block sweat glands," Dr. Frieling explains. "Without them, sweat flows freely, which can feel uncomfortable."That "flow" can also have a ripple effect on your laundry workload—break out the stain stick. "Without deodorant or antiperspirant, you may start seeing stains on your clothes," Dr. Kazlouskaya notes. "This happens because of the complex interaction between sweat composition, skin bacteria and fabric." Sweat is necessary to cool the body off. However, deodorant adds a layer of protection, reducing the odds that you sweat excessively."Excessive sweating can irritate the skin, causing chafing, bumps and folliculitis, which is inflammation of the hair follicles," Dr. Kazlouskaya says. "Sweat can be irritating, and it can increase bacterial growth, leading to small pimples or inflamed areas."Related: People may revert to 2020-style social distancing or start declining invites altogether. "You might notice people keeping a bit of distance from you," Dr. Kazlouskaya says. "That subtle shift can be a sign that your body odor is becoming stronger."Social connection is a key part of being human, so you may notice your mental health declines. On that note... Who knew that deodorant provided such a boost to your mental health (which can motivate you to take care of yourself physically)? "All of the above can make you more self-conscious and hesitant to engage with others," Dr. Kazlouskaya says. "A drop in self-esteem is a real consequence when you're not feeling the best." Plot twist. You may notice a few benefits from not applying deodorant (but that doesn't mean you should stop altogether)."Your skin may thank you depending on the type of deodorant you are using, especially if you are using a chemical deodorant," Dr. Chacon says. "You may see improved skin health. Even taking just a week off will reduce your chemical exposure to harsh ingredients like aluminum, which can cause some health concerns. This is especially important if you have sensitive skin and notice more reactions in your skin."To avoid this mishap, Dr. Kazlouskaya suggests avoiding deodorants that don't work for your body. "A good deodorant shouldn't cause itching, redness or irritation," she advises. "If it does, stop using it immediately. If irritation persists, see a dermatologist."Related: "Usually, daily application is sufficient for most people, but follow the instructions on the product label and listen to your body," Dr. Kazlouskaya explains. Indeed, there's some nuance. "There's no strict rule," she explains. "Some ingredients target odor by reducing bacteria—true deodorants—while others block sweat glands—antiperspirants. If your deodorant includes an antiperspirant, it's often best to apply it in the evening for maximum effectiveness." Dr. Chacon is a fan of morning deodorant applications. "That way, you can feel confident that your deodorant is doing its job and covering any odor for the day," she says. "You can always reapply if you find yourself sweating more than that day, especially if you worked out, and smell an odor sooner than the end of the day or if you have taken a shower midday and need to reapply because it was washed off." Up Next:Dr. Anna Chacon, MD, a dermatologist Dr. Gretchen W. Frieling, MD, a triple board-certified dermatopathologist at GFaceMD Dr. Viktoryia Kazlouskaya, MD, Ph.D., a dermatologist If You Skip Deodorant for a Week, Here's What Happens to Your Body first appeared on Parade on Jul 5, 2025 This story was originally reported by Parade on Jul 5, 2025, where it first appeared.
